Clinical effects of antidiabetic drugs on psoriasis: The perspective of evidence-based medicine

World J Diabetes. 2021 Aug 15;12(8):1141-1145. doi: 10.4239/wjd.v12.i8.1141.

Abstract

Psoriasis and diabetes shared common underlying pathophysiological mechanisms. Emerging data suggested that antidiabetic medications may improve the psoriasis severity in patients with diabetes mellitus. Several hypoglycemic agents including thiazolidinediones, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and biguanides have been reported to make a remarkable reduction in the Psoriasis Area and Severity Index score from baseline. This antipsoriatic effect could be mediated not only by the glucose-lowering action of these agents but also via inhibition of keratinocyte over proliferation, increase expression of differentiation markers, suppression the immune inflammatory pathway, and blocking the calcium channels and mitogen-activated protein kinase signaling pathways. On the other hand, there was no significant increase in adverse reactions associated with the treatment of pioglitazone or metformin. However, previous studies often had the relatively short duration of the trials, and did not have enough power to assess recurrence of psoriasis. Potential bias in the study and missing data could undermine the reliability of the results. Therefore, the appropriately randomized controlled studies with large sample sizes and long-term durations in various psoriasis patients are warranted for further support.

Keywords: Antipsoriatic effect; Biguanides; Dipeptidyl peptidase-4 inhibitors; Evidence-based medicine; Glucagon-like peptide-1 receptor agonists; Hypoglycemic agents; Psoriasis; Thiazolidinediones.

Publication types

  • Editorial